Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use [PMID: 41589628] Laboratory literature summary: Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use
Each pathway contributes a separate pharmacological signal: GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling in the hypothalamus GIP receptor agonism enhances glucose-dependent insulin secretion and is associated in the literature with effects on lipid handling Glucagon receptor agonism increases energy expenditure and hepatic glucose output, the opposite direction to a glucagon antagonist, and is absent from every dual agonist currently on the UK market How retatrutide compares to dual agonists Tirzepatide (Mounjaro) is a GIP + GLP-1 dual agonist authorised by the MHRA for type 2 diabetes in 2023
At ZYP Medical , we specialize in helping men like you lose weight, regain confidence, and feel like themselves again
Unlocking ferroptosis: A novel link between triple-negative breast cancer and immune regulation
Safety Guide Wegovy (semaglutide 2.4 mg) can generally be taken safely after gallbladder removal, as cholecystectomy is not listed as a contraindication by the MHRA
We can ease the burden of her medication regimen and simplify it for her
